Clinical relevance of advanced glycation endproducts for vascular surgery.
Atherosclerosis is the main contributor to cardiovascular disease and leads to intimal plaque formation, which may progress to plaque rupture with subsequent thromboembolic events and/or occlusion of the arterial lumen. There is increasing evidence that the development or progression of atherosclerosis is associated with advanced glycation endproducts (AGEs). AGEs are a heterogeneous group of compounds formed by the non-enzymatic reaction of reducing sugars with proteins, lipids, and nucleic acids. An increased understanding of the mechanisms of formation and interaction of AGEs has allowed the development of several potential anti-AGE strategies. This review summarizes AGE formation and biochemistry, the pathogeneic role of AGEs in cardiovascular disease, anti-AGE therapies and clinical relevance to vascular surgery.
Meerwaldt
R
R
Department of Surgery, Isala Clinics, Zwolle, The Netherlands.
van der Vaart
M G
MG
Department of Surgery (Division of Vascular Surgery), University Medical Center Groningen, Groningen, The Netherlands.
van Dam
G M
GM
Department of Surgery (Division of Vascular Surgery), University Medical Center Groningen, Groningen, The Netherlands.
Tio
R A
RA
Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands.
Hillebrands
J-L
JL
Department of Cell Biology (University of Groningen), University Medical Center Groningen, Groningen, The Netherlands.
Smit
A J
AJ
Department of Internal Medicine (Division of Vascular Medicine), University Medical Center Groningen, Groningen, The Netherlands.
Zeebregts
C J
CJ
Department of Surgery (Division of Vascular Surgery), University Medical Center Groningen, Groningen, The Netherlands. Electronic address: czeebregts@hotmail.com.
D050197:Atherosclerosis / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery; D015415:Biomarkers / Q000378:metabolism; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D017719:Diabetic Foot / Q000378:metabolism* / Q000503:physiopathology / Q000601:surgery; D018450:Disease Progression; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000378:metabolism; D006801:Humans; D015607:Stents; D016896:Treatment Outcome; D014654:Vascular Patency; D014656:Vascular Surgical Procedures / Q000009:adverse effects / Q000295:instrumentation
D015415:Biomarkers; D017127:Glycation End Products, Advanced